Care Begins Within Because Ingredients Matter: Lenzing's VEOCEL™ Champions Sustainable Innovation at IDEA25 and CIDPEX
VEOCEL™ highlighted its innovative, environmentally responsible fibers for hygiene and personal care single-use products at CIDPEX and IDEA25 With VEOCEL™ Lyocell, Lenzing invites partners to unleash possibilities in single-use – not only meeting...
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been...
NetDragon Participates in Digital China Summit for the 8th Consecutive Year, Pioneering AI-Driven Innovation in Gaming and Education
HONG KONG, May 7, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 0777), a global leader in building internet communities, is pleased to announce its participation in the 8th Digital China...
Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity
HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obesity, will be...
Gamma Communications Recognized with Frost & Sullivan's 2024 European UCaaS Competitive Strategy Leadership Award
The company has shown exceptional strategy execution, innovation, and customer-centric growth in a rapidly evolving market. SAN ANTONIO, Texas, May 6, 2025 /PRNewswire/ -- Frost & Sullivan is proud to present Gamma Communications with the 2024...
IND Application for NTS071, Nutshell Therapeutics' p53 Y220C Allosteric Reactivator, Received US FDA clearance
SHANGHAI, May 4, 2025 /PRNewswire/ -- On April 23, 2025, Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate P hase 1 clinical trial in the United States for its NTS071, a novel small molecule allosteric...
A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis
SUZHOU, China, May 1, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that a phase II/III clinical trial of anti-HER2 bispecific antibody KN026...
Amorepacific Research Confirms Potential of Microalgal-Derived PDRNs in Skin Regeneration and Wound Healing
New findings suggest 'BluePDRN™' offers a sustainable, scalable alternative to traditional animal-derived PDRNs SEOUL, South Korea, April 29, 2025 /PRNewswire/ -- Amorepacific revealed research findings confirming the skin-regenerative effects of...
Antaisolar Shines at Green Energy Expo 2025 in Korea with BIPV and Versatile Mounting Solutions
DAEGU, South Korea, April 28, 2025 /PRNewswire/ -- From April 23 to 25, 2025, Antaisolar made a strong appearance at Green Energy Expo 2025 in Daegu, South Korea, showcasing its latest BIPV systems, rooftop mounting structures, and ground-mounted...
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg , and 40 mg doses. - ASC30 oral once-daily tablet also...